Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Show more

Location: 116 Huntington Avenue, Boston, MA, 02116, United States | Website: https://www.bicara.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

946.1M

52 Wk Range

$7.80 - $19.71

Previous Close

$17.27

Open

$17.27

Volume

108,572

Day Range

$16.71 - $17.30

Enterprise Value

657.9M

Cash

290.2M

Avg Qtr Burn

-28.25M

Insider Ownership

12.14%

Institutional Own.

91.82%

Qtr Updated

09/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.